Use of Bamlanivimab and Etesevimab to Treat COVID-19 Resumes
August 27, 2021Tecentriq Breast Cancer Indication Withdrawn
August 27, 2021August 27, 2021 – Teligent Pharma is recalling one lot of Lidocaine HCl Topical Solution 4%, 50mL, packaged in a screw cap glass bottle. This recall extends to the user level. Testing has found the affected lot to be super potent.
- There is no impact to members through Benecard Central Fill.
- The recalled product is used to provide pain relief to the mouth, nose, and throat.
- Superpotency describes when a drug is stronger than it should be. Individuals who use the recalled lidocaine may receive a higher than intended dose, which could cause potentially severe or fatal local anesthetic systemic toxicity. Teligent Pharma had not received any reports of adverse events related to the affected lidocaine as of the recall date.
- Teligtent Pharma is notifying its distributors of the recall and arranging for return of the affected product. Distributors, consumers, and patients in possession of the recalled lidocaine should return it to their place of purchase.
- Questions about the recall can be directed to Teligent Pharma at 1-856-697-1441 (press *) or Medical@teligent.com. Patients who have experienced any problems that may be related to use of the affected lidocaine should contact their healthcare provider.
- A copy of the full recall announcement is available on the FDA's website.